Edgewise Therapeutics, Inc. (NASDAQ:EWTX – Get Rating) – Equities research analysts at Wedbush issued their Q1 2023 EPS estimates for shares of Edgewise Therapeutics in a research note issued on Wednesday, May 11th. Wedbush analyst L. Chico expects that the company will earn ($0.49) per share for the quarter. Wedbush also issued estimates for Edgewise Therapeutics’ Q2 2023 earnings at ($0.51) EPS, Q3 2023 earnings at ($0.50) EPS and Q4 2023 earnings at ($0.52) EPS.
A number of other equities analysts have also recently commented on the stock. Zacks Investment Research raised shares of Edgewise Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 1st. The Goldman Sachs Group assumed coverage on shares of Edgewise Therapeutics in a report on Friday, January 28th. They set a “neutral” rating for the company. Royal Bank of Canada assumed coverage on shares of Edgewise Therapeutics in a report on Wednesday, April 13th. They set an “outperform” rating and a $31.00 price objective for the company. JPMorgan Chase & Co. decreased their price objective on shares of Edgewise Therapeutics from $33.00 to $32.00 and set an “overweight” rating for the company in a report on Monday, February 14th. Finally, SVB Leerink reiterated an “outperform” rating on shares of Edgewise Therapeutics in a report on Monday, April 25th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, Edgewise Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $29.67.
Edgewise Therapeutics (NASDAQ:EWTX – Get Rating) last released its quarterly earnings results on Wednesday, May 11th. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.02).
Several large investors have recently bought and sold shares of EWTX. Citigroup Inc. raised its holdings in shares of Edgewise Therapeutics by 155.0% in the 3rd quarter. Citigroup Inc. now owns 1,497 shares of the company’s stock valued at $25,000 after purchasing an additional 910 shares in the last quarter. Legal & General Group Plc raised its holdings in shares of Edgewise Therapeutics by 149.4% in the 4th quarter. Legal & General Group Plc now owns 4,651 shares of the company’s stock valued at $71,000 after purchasing an additional 2,786 shares in the last quarter. Sfmg LLC bought a new stake in shares of Edgewise Therapeutics in the 1st quarter valued at about $98,000. Virtus ETF Advisers LLC bought a new stake in shares of Edgewise Therapeutics in the 4th quarter valued at about $131,000. Finally, Metropolitan Life Insurance Co NY bought a new stake in shares of Edgewise Therapeutics in the 4th quarter valued at about $170,000.
Edgewise Therapeutics Company Profile (Get Rating)
Edgewise Therapeutics, Inc, a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial.
- Get a free copy of the StockNews.com research report on Edgewise Therapeutics (EWTX)
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
- Carvana Insiders Buy Shares But Maybe You Shouldn’t
- Dutch Bros Gets Scalded By Inflation
Receive News & Ratings for Edgewise Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edgewise Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.